Twenty-first Century Drug Discovery an Expanding Landscape /

‘Twenty-first Century Drug Discovery – an Expanding Landscape’ follows on from the author’s previous book ‘The Science and Business of Drug Discovery – Demystifying the Jargon’, published by Springer as a second edition in 2020. While many of the key scientific and commercial features of drug discov...

詳細記述

保存先:
書誌詳細
第一著者: Zanders, Edward D. (著者)
団体著者: SpringerLink (Online service)
フォーマット: 電子媒体 eBook
言語:英語
出版事項: Cham : Springer Nature Switzerland : Imprint: Springer, 2025.
版:1st ed. 2025.
主題:
オンライン・アクセス:https://doi.org/10.1007/978-3-031-93949-5
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

MARC

LEADER 00000nam a22000005i 4500
001 978-3-031-93949-5
003 DE-He213
005 20260810170516.0
007 cr nn 008mamaa
008 250618s2025 sz | o |||| 0|eng d
020 |a 9783031939495  |9 978-3-031-93949-5 
024 7 |a 10.1007/978-3-031-93949-5  |2 doi 
050 4 |a TP248.13-248.65 
072 7 |a TCB  |2 bicssc 
072 7 |a SCI010000  |2 bisacsh 
072 7 |a TCB  |2 thema 
082 0 4 |a 660.6  |2 23 
100 1 |a Zanders, Edward D.  |e author.  |0 (orcid)0000-0003-4323-2007  |1 https://orcid.org/0000-0003-4323-2007  |4 aut  |4 http://id.loc.gov/vocabulary/relators/aut 
245 1 0 |a Twenty-first Century Drug Discovery  |h [electronic resource] :  |b an Expanding Landscape /  |c by Edward D. Zanders. 
250 |a 1st ed. 2025. 
264 1 |a Cham :  |b Springer Nature Switzerland :  |b Imprint: Springer,  |c 2025. 
300 |a 1 online resource (XV, 244 p. 63 illus.).  |b 44 illus. in color. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
341 0 |b Table of contents navigation  |2 onix 
341 0 |b Single logical reading order  |2 onix 
341 0 |b Short alternative textual descriptions  |2 onix 
341 0 |b Use of color is not sole means of conveying information  |2 onix 
341 0 |b Use of high contrast between text and background color  |2 onix 
341 0 |b Next / Previous structural navigation  |2 onix 
341 0 |b All non-decorative content supports reading without sight  |2 onix 
347 |a text file  |b PDF  |2 rda 
505 0 |a Part I. Current State of Drug Discovery and Development -- Chapter 1. Introduction -- Chapter 2. Overview of Current Drug Discovery and Development -- Chapter 3. Computational Approaches to Drug Discovery -- Part II. Emerging Opportunities -- Chapter 4. Points of Scientific Impact -- Chapter 5. Hunting for Targets -- Chapter 6. Interventions -- Chapter 7. Development and Implementation. 
520 |a ‘Twenty-first Century Drug Discovery – an Expanding Landscape’ follows on from the author’s previous book ‘The Science and Business of Drug Discovery – Demystifying the Jargon’, published by Springer as a second edition in 2020. While many of the key scientific and commercial features of drug discovery described in the latter are essentially unchanged since publication, the underlying science has advanced rapidly thereby presenting a broad landscape of opportunities for biopharmaceutical discovery in the twenty-first century and beyond. However, these wide-ranging and complex discovery opportunities are difficult to convey in a short period of time. This book overcomes the problem by giving readers time to study the relevant material at their leisure. Starting with a short overview of the current technical and commercial background to drug discovery and development, the book focuses on the discovery of novel targets and therapeutic agents. The latter are no longer just small molecules, but include engineered proteins, microbes and immune cells created as a result of advances in molecular cell biology and computational methods, among others. These discovery activities are presented as part of a group of ‘systems’ under the headings of Genetics, Cell Biology, Microbiome, Immune and Nervous Systems, none of which are mutually exclusive and all of which depend upon lab-based and computational technologies. These technologies are covered in some detail, highlighting in particular, single molecule and cell analysis, selective drug target degradation and machine learning. 
532 8 |a Accessibility summary: This PDF does not fully comply with PDF/UA standards, but does feature limited screen reader support, described non-text content (images, graphs), bookmarks for easy navigation and searchable, selectable text. Users of assistive technologies may experience difficulty navigating or interpreting content in this document. We recognize the importance of accessibility, and we welcome queries about accessibility for any of our products. If you have a question or an access need, please get in touch with us at accessibilitysupport@springernature.com. 
532 8 |a No reading system accessibility options actively disabled 
532 8 |a Publisher contact for further accessibility information: accessibilitysupport@springernature.com 
588 |a Print version record. 
650 0 |a Biotechnology. 
650 0 |a Pharmaceutical chemistry. 
650 0 |a Pharmacology. 
650 1 4 |a Biotechnology. 
650 2 4 |a Pharmaceutics. 
650 2 4 |a Pharmacology. 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer Nature eBook 
776 0 8 |i Printed edition:  |z 9783031939488 
776 0 8 |i Printed edition:  |z 9783031939501 
776 0 8 |i Printed edition:  |z 9783031939518 
856 4 0 |u https://doi.org/10.1007/978-3-031-93949-5 
912 |a ZDB-2-SBL 
912 |a ZDB-2-SXB 
912 |a ZDB-2-237 
950 |a Biomedical and Life Sciences (SpringerNature-11642) 
950 |a Biomedical and Life Sciences (R0) (SpringerNature-43708) 
950 |a Focus Bundle Biomedical and Human Health Sciences (SpringerNature-85407)